Tang Yun, Zhang You-Jing, Wu Zeng-Hong
Department of Critical Care Medicine, Union Hospital.
School of Public Health.
Medicine (Baltimore). 2020 Apr;99(14):e19054. doi: 10.1097/MD.0000000000019054.
Lung adenocarcinoma (LUAD), a form of lung cancer, is reported to cause first and second-order cancer morbidity to men and women in China, respectively. We assessed the mRNA expression of GJB2 in LUAD patients in our study, based on data acquired from the cancer genome atlas (TCGA) and so as to increase further knowledge into the biological pathways involved in LUAD pathogenesis related to GJB2.Information on gene expression and comparing clinical data were recognized and downloaded from TCGA. Gene set enrichment analysis (GSEA) created an arranged list of all genes is indicated by their connection with GJB2 expression.Our study cohort included 265 (54.5%) female and 221 (36.0%) male patients. The scatter plot and paired plot showed the difference of GJB2 expression between normal and tumor samples (P < .01). Overall survival (OS) analysis demonstrated that LUAD with GJB2 -high had a more terrible prognosis than that with GJB2 -low (P < .01). Multivariate analysis with the cox proportional hazards model indicated that the expression of Cx26 (HR: 1.00; 95%CI: 1.00-1.01; P = .041) and stage (HR: 1.95; 95%CI: 1.23-3.09; P = .003) were independent prognostic factors for patients with LUAD. The GSEA results showed that cytosolic DNA sensing pathway, apoptosis, cytokine-cytokine receptor interaction, natural killer cell mediated cytotoxicity, regulation of actin cytoskeleton, toll-like receptor signaling pathway, small cell lung cancer and pathways in cancer are differentially enriched in GJB2 high expression phenotype.Our study confirmed the significantly high levels of Cx26 expression in LUAD patients with several observed clinical features. GJB2 may be a potentially useful prognostic molecular biomarker of bad survival in LUAD, while further experimental ought to be performed to demonstrate the biologic effect of GJB2.
肺腺癌(LUAD)是肺癌的一种形式,据报道在中国分别导致男性和女性的一级和二级癌症发病率。在我们的研究中,我们基于从癌症基因组图谱(TCGA)获取的数据评估了LUAD患者中GJB2的mRNA表达,以便进一步了解与GJB2相关的LUAD发病机制中涉及的生物学途径。从TCGA识别并下载了基因表达信息和比较临床数据。基因集富集分析(GSEA)创建了一份所有基因的有序列表,这些基因通过它们与GJB2表达的关联来表示。我们的研究队列包括265名(54.5%)女性和221名(36.0%)男性患者。散点图和配对图显示了正常样本和肿瘤样本之间GJB2表达的差异(P<0.01)。总生存期(OS)分析表明,GJB2高表达的LUAD患者的预后比GJB2低表达的患者更差(P<0.01)。使用Cox比例风险模型进行的多变量分析表明,Cx26的表达(HR:1.0;95%CI:1.00 - 1.01;P = 0.041)和分期(HR:1.95;95%CI:1.23 - 3.09;P = 0.003)是LUAD患者的独立预后因素。GSEA结果表明,胞质DNA传感途径、凋亡、细胞因子 - 细胞因子受体相互作用、自然杀伤细胞介导的细胞毒性、肌动蛋白细胞骨架调节、Toll样受体信号通路、小细胞肺癌和癌症中的途径在GJB2高表达表型中差异富集。我们的研究证实了在具有几种观察到的临床特征的LUAD患者中Cx26表达水平显著升高。GJB2可能是LUAD患者不良生存的一种潜在有用的预后分子生物标志物,而应该进行进一步的实验来证明GJB2的生物学效应。